基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

已收盘 05-14 16:09:14

8.150

+0.280

+3.56%

最高8.270	最低7.920	成交量1,482万
今开8.000	昨收7.870	日振幅4.45%
总市值130.40亿	流通市值130.40亿	总股本16.00亿
成交额1.20亿	换手率0.93%	流通股本16.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":8.15,"timestamp":1778746154004,"preClose":7.87,"halted":0,"volume":14817523,"delay":0,"changeRate":0.03557814485387551,"floatShares":1600000000,"shares":1600000000,"eps":-0.314752,"marketStatus":"已收盘","change":0.28,"latestTime":"05-14 16:09:14","open":8,"high":8.27,"low":7.92,"amount":120458309,"amplitude":0.044473,"askPrice":8.15,"askSize":288500,"bidPrice":8.14,"bidSize":53500,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778808600000},"marketStatusCode":5,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":7.87,"openAndCloseTimeList":[[1778722200000,1778731200000],[1778734800000,1778745600000]],"volumeRatio":1.803333,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616/tweets","defaultTab":"tweets","newsList":[{"id":"1154471918","title":"异动解读 | 基石药业-B盘中大涨5.08%，拟回购股份及核心产品临床数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1154471918","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154471918?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:41","pubTimestamp":1778730071,"startTime":"0","endTime":"0","summary":"基石药业-B(02616)今日盘中大涨5.08%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，拟于公开市场上回购最多不超过1.36亿股股份，此举彰显了公司管理层及董事会对自身研发成果、商业化进展与长期业务发展的坚定信心，并体现了公司高度重视股东价值回报的理念。同时，公司核心产品CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的最新临床数据即将于ASCO年会公布，这一进展进一步增强了市场对公司未来增长潜力的预期，从而推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635000432","title":"基石药业-B(02616)拟于公开市场上购回最多不超过1.36亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635000432","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635000432?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:58","pubTimestamp":1778666335,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，根据本公司股东于本公司2025年6月25日举行的股东周年大会上批准的购回股份的一般授权及(如适用)未来股东于本公司不时的股东大会上批准的购回股份的任何一般授权(购回授权)，其拟不时于公开市场上购回最多不超过1.36亿股股份。本公司核心产品CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的最新临床数据即将于ASCO年会公布。适时实施购回股份计划，充分彰显本公司管理层及董事会对自身研发成果、商业化进展与长期业务发展的坚定信心。亦体现本公司高度重视股东价值回报、持续完善资本回馈机制的理念。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)拟于公开市场上购回最多不超过1.36亿股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634342270","title":"基石药业-B(02616)启动地产化普拉替尼胶囊全国商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2634342270","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634342270?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:08","pubTimestamp":1778458113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司高选择性RET抑制剂普拉替尼胶囊的首批地产化产品已完成生产及放行，并正式启动全国商业化发货。受益于国家医保目录准入对患者可及性的显著提升，截至2026年4月，普拉替尼胶囊的终端销售量较去年同期快速增长超430%。基于这一增长趋势，预计2026年全年普拉替尼胶囊销售收入有望超过人民币3亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)启动地产化普拉替尼胶囊全国商业化发货","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125457924","title":"基石药业-B启动国产普拉替尼胶囊全国商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1125457924","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125457924?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:01","pubTimestamp":1778457676,"startTime":"0","endTime":"0","summary":"基石药业-B宣布，其本土生产的普拉替尼胶囊已正式开始在全国范围内进行商业化供应。这一举措标志着该产品在中国市场进入全面商业化的新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120255555","title":"基石药业-B 4月新增1.24亿股，股本升至16.00亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120255555","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120255555?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:06","pubTimestamp":1778144779,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年5月7日发布2026年4月股份变动月报。公告显示，公司截至本月末的注册股本仍为2,000,000,000股、面值0.0001美元，法定股本为200,000美元，均与上月保持不变。根据月报披露信息，4月末已发行股份由上月底的1,476,018,722股上升至1,600,249,187股，当月累计新增124,230,465股。截至月末，公司库存股份数为0股，未发生购回或注销行为。公司确认其已充分符合香港联交所相关上市规则、法律及监管要求，并表示上述股份发行及期权行使均经董事会正式授权和批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177023630","title":"异动解读 | 基石药业-B盘中大跌5.17%，配股稀释与业绩亏损双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1177023630","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177023630?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:27","pubTimestamp":1777361238,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.17%，引起了市场的广泛关注。消息面上，公司近期完成了大规模股份发行，根据配售协议以每股8.97港元的价格配发了约1.18亿股新股，占配发前已发行股本约7.99%，同时通过受限制股份奖励计划再发行了600万股。这使得公司股本在短期内显著扩大，股权稀释压力明显，且配售价较市价存在折价，导致市场抛压持续释放。此外，公司最新披露的年度业绩显示，其收入同比下滑33.8%至约2.70亿元人民币，年内亏损则从约0.91亿元大幅扩大至4.37亿元，研发投入也有所增加，经营压力上升。配股带来的稀释效应与基本面承压的双重因素叠加，共同导致了股价的下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159919357","title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1159919357","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159919357?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:06","pubTimestamp":1777284381,"startTime":"0","endTime":"0","summary":"基石药业-B于2025年年度实现收入约2.70亿元人民币，较上一年度的4.07亿元减少33.8%，主要受商业化与授权收入下降影响。同期收入成本为2.18亿元，毛利约0.51亿元。研发投入增至3.12亿元，较此前1.35亿元大幅提升，主要因关键临床试验和新药项目加速推进。销售及市场推广开支约0.83亿元，行政开支约0.89亿元。整体来看，年内亏损从上一年度约0.91亿元扩大至4.37亿元，经营压力显著上升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145260957","title":"异动解读 | 基石药业-B盘中大跌5.90%，大额配股稀释效应持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1145260957","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145260957?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:04","pubTimestamp":1776996250,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.90%，引起了市场的广泛关注。消息面上，公司此前根据配售协议以每股8.97港元的价格配发及发行1.18亿股新股，占配发前已发行股本约7.99%，总筹资约10.53亿港元。此外，公司于4月23日通过受限制股份奖励计划再发行600万股新股。短期内大规模新股发行导致股本从约14.76亿股扩大至约16亿股，股权稀释压力显著，叠加配售价较当前股价存在折价，市场抛压持续释放。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181091599","title":"基石药业-B：4月23日发行600万股，占已发行股本约0.376%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181091599","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181091599?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:36","pubTimestamp":1776947762,"startTime":"0","endTime":"0","summary":"基石药业-B（02616）于2026年4月23日发布公告，披露公司通过其受限制股份奖励计划发行6,000,000股新股份，约占发行前已发行股本的0.376%。每股发行价为USD0.0001。此次发行完成后，公司已发行股本增至1,600,239,783股。\n公司在公告中确认，相关股份发行已获得董事会正式授权并遵守香港联合交易所有限公司证券上市规则及其他适用法律法规。公告由公司董事李伟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B：4月23日发行600万股，占已发行股本约0.376%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160291683","title":"异动解读 | 基石药业-B发行1.18亿股新股，盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160291683","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160291683?lang=zh_cn&edition=full","pubTime":"2026-04-23 11:24","pubTimestamp":1776914647,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.02%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，根据2026年4月14日的配售协议，于2026年4月22日以一般授权配发及发行1.18亿股新股份。此次发行新股可能导致股权稀释，从而对股价产生压力。市场分析人士指出，新股发行通常会增加流通股数量，可能影响每股收益，投资者因此抛售股票，导致股价下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629425042","title":"基石药业-B(02616)根据配售协议发行1.18亿股新股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629425042","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629425042?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:43","pubTimestamp":1776865439,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，根据2026年4月14日的配售协议于2026年4月22日以一般授权配发及发行1.18亿股新股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192948925","title":"基石药业-B：4月22日配发1.18亿新股，涉资约10.58亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192948925","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192948925?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:36","pubTimestamp":1776865011,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年4月22日发布公告，披露其已发行股本出现变动。公告称，公司在2026年4月1日至4月22日期间，因多次行使雇员持股计划授予的期权发行普通股共计221,061股，发行价格区间介乎每股港币0.39港元至4.619港元。此外，公司于4月22日根据4月14日签订的配售协议，以一般授权配发及发行118,000,000股新股，约占配发前已发行股本的7.99%，发行价格为每股8.97港元，涉资约10.58亿港元。本次发行完成后，公司已发行股本由1,476,018,722股增至1,594,239,783股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"基石药业-B：4月22日配发1.18亿新股，涉资约10.58亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115060099","title":"异动解读 | ASCO年会公布关键临床数据叠加机构增持，基石药业-B盘中大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115060099","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115060099?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:34","pubTimestamp":1776821687,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大幅上涨5.10%，引起市场关注。披露内容将涵盖CS2009在非小细胞肺癌一线及后线治疗中的I/II期临床试验数据，以及在晚期实体瘤患者中的I期临床延长随访结果。根据香港联交所权益披露文件，高瓴资本旗下HHLR于4月15日斥资约2.35亿港元增持公司2620万股，持股比例升至6.01%。同日，摩根士丹利也增持了约795.92万股，涉资约7541.72万港元。两家知名投资机构的同步增持，显著增强了市场对该公司未来发展的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629067754","title":"基石药业-B早盘高开近5% 将于2026年ASCO年会公布CS2009多项临床关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629067754","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629067754?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:29","pubTimestamp":1776821340,"startTime":"0","endTime":"0","summary":"　　基石药业-B早盘高开近5%，截至发稿，股价上涨4.99%，现报10.3港元，成交额321.36万港元。　　4月22日，基石药业-B发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的多项临床关键进展，将在今年美国临床肿瘤学会年会通过两份壁报正式发布，披露内容将涵盖CS2009在非小细胞肺癌伫列中的I/II期临床试验数据 ，以及在晚期实体瘤患者中的I期临床延长随访结果。　　公告称，CS2009全球多中心I/II期临床试验正在澳大利亚和中国同步迅速推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-22/doc-inhvitah5636524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629061051","title":"基石药业-B(02616)将在美国临床肿瘤学会年会公布CS2009的多项临床关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629061051","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629061051?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:07","pubTimestamp":1776816445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的多项临床关键进展，将在今年美国临床肿瘤学会年会通过两份壁报正式发布，披露内容将涵盖CS2009在非小细胞肺癌伫列中的I/II期临床试验数据 ，以及在晚期实体瘤患者中的I期临床延长随访结果。更加成熟的安全性与PK/PD数据: 基石药业将于ASCO公布临床I期更大人群的延长随访数据，全面呈现CS2009的安全性、耐受性、药代动力学/药效动力学特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629367990","title":"HHLR Advisors, Ltd.增持基石药业-B(02616)2620万股 每股作价8.97港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629367990","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629367990?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:50","pubTimestamp":1776772235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月15日，HHLR Advisors, Ltd.增持基石药业-B(02616)2620万股，每股作价8.97港元，总金额约为2.35亿港元。增持后最新持股数目为8866.45万股，持股比例为6.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794281","title":"基石药业-B(02616)携CS5007(EGFR/HER3)等三款全新/差异化ADC临床前研究成果亮相AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794281","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628794281?lang=zh_cn&edition=full","pubTime":"2026-04-20 08:04","pubTimestamp":1776643475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司在2026年4月17日至22日召开的美国癌症研究协会年会上展出包括CS5007、CS5006及CS5008在内三项自主研发管线的临床前最新研究成果。CS5007是一种双特异性ADC,由抗EGFR/HER3人源IgG1抗体、基石药业专有的亲水性CSL20连接子，以及临床验证的拓扑异构酶I抑制剂Exatecan组成。此外，CS5008抗体产量高、ADC稳定性强、成药性良好。基石药业计划于2026年下半年正式启动CS5008的IND申请工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1161","BK4231","ADC","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101991349","title":"异动解读 | 基石药业-B盘中大涨5.05%，因配售股份筹资10.53亿港元用于研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1101991349","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101991349?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:17","pubTimestamp":1776305854,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大涨5.05%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，公司已与配售代理订立配售协议，以每股8.97港元的价格，向不少于六名承配人配售合共1.18亿股股份。假设所有配售股份获悉数认购，配售所得款项净额估计约为10.53亿港元。此举被市场视为对公司未来研发能力和增长潜力的积极信号，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627607257","title":"港股异动 | 基石药业-B(02616)涨超4% 拟合共配售1.18亿股份净筹10.53亿港元 进一步研发“管线”2.0资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2627607257","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627607257?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:00","pubTimestamp":1776304855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超4%，截至发稿，涨4.44%，报10.34港元，成交额3018.58万港元。消息面上，基石药业-B发布公告，于2026年4月14日，本公司与配售代理订立配售协议，本公司已有条件同意透过配售代理，以每股配售股份8.97港元的价格，向不少于六名承配人配售合共1.18亿股配售股份。假设所有1.18亿股配售股份获悉数认购，于配售完成后，配售所得款项总额将为10.58亿港元，配售所得款项净额估计为10.53亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","02616","BK1574","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627342004","title":"基石药业-B(02616)拟配售合共1.18亿股配售股份 净筹约10.53亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627342004","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627342004?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:28","pubTimestamp":1776209318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，于2026年4月14日，本公司与配售代理订立配售协议，本公司已有条件同意透过配售代理，以每股配售股份8.97港元的价格，向不少于六名承配人配售合共1.18亿股配售股份。配售股份将根据一般授权配发及发行，且无需取得任何股东批准。假设所有1.18亿股配售股份获悉数认购，于配售完成后，配售所得款项总额将为10.58亿港元，配售所得款项净额估计为10.53亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.0817},{"period":"1month","weight":-0.2051},{"period":"3month","weight":0.4206},{"period":"6month","weight":0.2944},{"period":"1year","weight":2.0623},{"period":"ytd","weight":0.4934}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0284},{"period":"3month","weight":-0.0238},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1419},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.064189},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}